CIK 0000921114 · Non-accelerated filer<br>Smaller reporting company
Armata Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ARMP
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 911549568
- Phone
- 310-665-2928
- Business address
- 5005 MCCONNELL AVE, LOS ANGELES, CA, 90066
- Former names
- AmpliPhi Biosciences Corp, TARGETED GENETICS CORP /WA/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-14 | Odysseas Kostas D Director | Grant or award · Stock Options (Right to Buy) | +54,343 | 94,009 | ||
| 2024-03-14 | Birx Deborah Chief Executive Officer | Grant or award | +60,000 | 260,000 | ||
| 2024-03-14 | Birx Deborah Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +240,000 | 240,000 | ||
| 2023-12-21 | Schlesinger Sarah J. Director | Grant or award · Stock Options (Right to Buy) | +10,461 | 10,461 | ||
| 2023-12-21 | Peterson Todd C. Director | Grant or award · Stock Options (Right to Buy) | +10,461 | 10,461 | ||
| 2023-12-21 | Kramer Robin Director | Grant or award · Stock Options (Right to Buy) | +10,461 | 10,461 | ||
| 2023-12-21 | PATTI JOSEPH M Director | Grant or award · Stock Options (Right to Buy) | +10,461 | 10,461 | ||
| 2023-12-21 | Rychlik Richard Corporate Controller and PFO | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2023-12-21 | Haimovitz Jules Director | Grant or award · Stock Options (Right to Buy) | +10,461 | 10,461 | ||
| 2023-12-21 | Birx Deborah Chief Executive Officer | Grant or award | +200,000 | 200,000 | ||
| 2023-12-21 | Birx Deborah Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +200,000 | 200,000 | ||
| 2023-12-21 | Odysseas Kostas D Director | Grant or award · Stock Options (Right to Buy) | +10,461 | 10,461 | ||
| 2023-01-10 | Innoviva, Inc. Director | Purchase · Convertible Debt convertible into Common Stock | +0 | $30,000,000.00 | $0 | |
| 2022-04-13 | Peterson Todd C. Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 | ||
| 2022-04-13 | Patrick Todd Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 | ||
| 2022-04-13 | Schlesinger Sarah J. Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 | ||
| 2022-04-13 | Kramer Robin Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 | ||
| 2022-04-13 | Odysseas Kostas D Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 | ||
| 2022-04-13 | PATTI JOSEPH M Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 | ||
| 2022-04-13 | Haimovitz Jules Director | Grant or award · Stock Options (Right to Buy) | +33,000 | 33,000 |
Page 3 of 7 · 122 trades